Escitalopram pharmacogenetics

CYP2C19 relationships with dosing and clinical outcomes in autism spectrum disorder

Jeffrey R. Bishop, Fedra Najjar, Leah H. Rubin, Stephen J. Guter, Thomas Owley, Matthew W. Mosconi, Suma Jacob, Edwin H. Cook

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background and aim Selective serotonin reuptake inhibitors such as escitalopram are commonly used to treat patients with autism spectrum disorder (ASD), but there are individual differences in treatment response and tolerability. CYP2C19 encodes the primary enzyme responsible for escitalopram metabolism and we investigated whether polymorphisms in CYP2C19 were related to symptoms and dosing in a pharmacogenetic study of ASD. Participants and methods Participants completed the Aberrant Behavior Checklist - Community Version (ABC-CV) weekly for 6 weeks. Escitalopram was initiated at a dose of 2.5 mg per day, with weekly increases to 20 mg unless intolerable side-effects occurred. Three CYP2C19 metabolizer groups, including ultrarapid, extensive, and reduced metabolizers, were examined in relation to symptom improvement and tolerated dose. Results ABC-CV scores improved over the course of treatment (P

Original languageEnglish (US)
Pages (from-to)548-554
Number of pages7
JournalPharmacogenetics and Genomics
Volume25
Issue number11
DOIs
StatePublished - Nov 11 2015

Fingerprint

Citalopram
Pharmacogenetics
Checklist
Serotonin Uptake Inhibitors
Individuality
Enzymes
Therapeutics
Cytochrome P-450 CYP2C19
Autism Spectrum Disorder

Keywords

  • Autism spectrum disorder
  • CYP2C19
  • Escitalopram

ASJC Scopus subject areas

  • Genetics
  • Molecular Biology
  • Molecular Medicine
  • Genetics(clinical)

Cite this

Bishop, J. R., Najjar, F., Rubin, L. H., Guter, S. J., Owley, T., Mosconi, M. W., ... Cook, E. H. (2015). Escitalopram pharmacogenetics: CYP2C19 relationships with dosing and clinical outcomes in autism spectrum disorder. Pharmacogenetics and Genomics, 25(11), 548-554. https://doi.org/10.1097/FPC.0000000000000173

Escitalopram pharmacogenetics : CYP2C19 relationships with dosing and clinical outcomes in autism spectrum disorder. / Bishop, Jeffrey R.; Najjar, Fedra; Rubin, Leah H.; Guter, Stephen J.; Owley, Thomas; Mosconi, Matthew W.; Jacob, Suma; Cook, Edwin H.

In: Pharmacogenetics and Genomics, Vol. 25, No. 11, 11.11.2015, p. 548-554.

Research output: Contribution to journalArticle

Bishop, JR, Najjar, F, Rubin, LH, Guter, SJ, Owley, T, Mosconi, MW, Jacob, S & Cook, EH 2015, 'Escitalopram pharmacogenetics: CYP2C19 relationships with dosing and clinical outcomes in autism spectrum disorder', Pharmacogenetics and Genomics, vol. 25, no. 11, pp. 548-554. https://doi.org/10.1097/FPC.0000000000000173
Bishop, Jeffrey R. ; Najjar, Fedra ; Rubin, Leah H. ; Guter, Stephen J. ; Owley, Thomas ; Mosconi, Matthew W. ; Jacob, Suma ; Cook, Edwin H. / Escitalopram pharmacogenetics : CYP2C19 relationships with dosing and clinical outcomes in autism spectrum disorder. In: Pharmacogenetics and Genomics. 2015 ; Vol. 25, No. 11. pp. 548-554.
@article{199d7eb7fb1644ea852e3ce7f638cc71,
title = "Escitalopram pharmacogenetics: CYP2C19 relationships with dosing and clinical outcomes in autism spectrum disorder",
abstract = "Background and aim Selective serotonin reuptake inhibitors such as escitalopram are commonly used to treat patients with autism spectrum disorder (ASD), but there are individual differences in treatment response and tolerability. CYP2C19 encodes the primary enzyme responsible for escitalopram metabolism and we investigated whether polymorphisms in CYP2C19 were related to symptoms and dosing in a pharmacogenetic study of ASD. Participants and methods Participants completed the Aberrant Behavior Checklist - Community Version (ABC-CV) weekly for 6 weeks. Escitalopram was initiated at a dose of 2.5 mg per day, with weekly increases to 20 mg unless intolerable side-effects occurred. Three CYP2C19 metabolizer groups, including ultrarapid, extensive, and reduced metabolizers, were examined in relation to symptom improvement and tolerated dose. Results ABC-CV scores improved over the course of treatment (P",
keywords = "Autism spectrum disorder, CYP2C19, Escitalopram",
author = "Bishop, {Jeffrey R.} and Fedra Najjar and Rubin, {Leah H.} and Guter, {Stephen J.} and Thomas Owley and Mosconi, {Matthew W.} and Suma Jacob and Cook, {Edwin H.}",
year = "2015",
month = "11",
day = "11",
doi = "10.1097/FPC.0000000000000173",
language = "English (US)",
volume = "25",
pages = "548--554",
journal = "Pharmacogenetics and Genomics",
issn = "1744-6872",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - Escitalopram pharmacogenetics

T2 - CYP2C19 relationships with dosing and clinical outcomes in autism spectrum disorder

AU - Bishop, Jeffrey R.

AU - Najjar, Fedra

AU - Rubin, Leah H.

AU - Guter, Stephen J.

AU - Owley, Thomas

AU - Mosconi, Matthew W.

AU - Jacob, Suma

AU - Cook, Edwin H.

PY - 2015/11/11

Y1 - 2015/11/11

N2 - Background and aim Selective serotonin reuptake inhibitors such as escitalopram are commonly used to treat patients with autism spectrum disorder (ASD), but there are individual differences in treatment response and tolerability. CYP2C19 encodes the primary enzyme responsible for escitalopram metabolism and we investigated whether polymorphisms in CYP2C19 were related to symptoms and dosing in a pharmacogenetic study of ASD. Participants and methods Participants completed the Aberrant Behavior Checklist - Community Version (ABC-CV) weekly for 6 weeks. Escitalopram was initiated at a dose of 2.5 mg per day, with weekly increases to 20 mg unless intolerable side-effects occurred. Three CYP2C19 metabolizer groups, including ultrarapid, extensive, and reduced metabolizers, were examined in relation to symptom improvement and tolerated dose. Results ABC-CV scores improved over the course of treatment (P

AB - Background and aim Selective serotonin reuptake inhibitors such as escitalopram are commonly used to treat patients with autism spectrum disorder (ASD), but there are individual differences in treatment response and tolerability. CYP2C19 encodes the primary enzyme responsible for escitalopram metabolism and we investigated whether polymorphisms in CYP2C19 were related to symptoms and dosing in a pharmacogenetic study of ASD. Participants and methods Participants completed the Aberrant Behavior Checklist - Community Version (ABC-CV) weekly for 6 weeks. Escitalopram was initiated at a dose of 2.5 mg per day, with weekly increases to 20 mg unless intolerable side-effects occurred. Three CYP2C19 metabolizer groups, including ultrarapid, extensive, and reduced metabolizers, were examined in relation to symptom improvement and tolerated dose. Results ABC-CV scores improved over the course of treatment (P

KW - Autism spectrum disorder

KW - CYP2C19

KW - Escitalopram

UR - http://www.scopus.com/inward/record.url?scp=84943194003&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943194003&partnerID=8YFLogxK

U2 - 10.1097/FPC.0000000000000173

DO - 10.1097/FPC.0000000000000173

M3 - Article

VL - 25

SP - 548

EP - 554

JO - Pharmacogenetics and Genomics

JF - Pharmacogenetics and Genomics

SN - 1744-6872

IS - 11

ER -